The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...

SanegeneBio and Genentech's agreement focuses on advancing RNAi therapeutics, emphasizing scalable genetic medicines beyond rare diseases. SanegeneBio's RNAi platform aims for durable gene silencing ...

Cardiovascular disease (CVD) is the leading cause of death globally, and combating this range of complex disorders presents numerous challenges. Scientists seek innovative approaches to address this ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

Nicholas Dreisbach (left) is a Senior Associate Scientist in the RNA team at ElevateBio (MA, USA), where he deploys his skills as an expert in capillary gel electrophoresis (CGE) technologies. His ...

A new national programme that aims to position Singapore at the forefront of advancements in RNA science and applications was officially launched today. This new initiative – named National Initiative ...